Skip to main content

Advertisement

SpringerLink
Log in

Response to: Prognosis of metastatic bone cancer and myeloma patients and long‑term risk of medication‑related osteonecrosis of the jaw (MRONJ): some critical points

  • Correspondence
  • Published:
Supportive Care in Cancer Aims and scope Submit manuscript

The Original Article was published on 27 July 2022

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Data availability

The datasets used and/or analyzed during the current study are not openly or universally available because they contain patient data. Datasets are available from the corresponding author on reasonable request.

References

  1. Hata H, Imamachi K, Ueda M, Matsuzaka M, Hiraga H, Osanai T, Harabayashi T, Fujimoto K, Oizumi S, Takahashi M, Yoshikawa K, Sato J, Yamazaki Y, Kitagawa Y (2022) Prognosis by cancer type and incidence of zoledronic acid-related osteonecrosis of the jaw: a single-center retrospective study. Support Care Cancer 30:4505–4514. https://doi.org/10.1007/s00520-022-06839-4

    Article  PubMed  Google Scholar 

  2. Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thurlimann B, Senn HJ, Panel members (2011) Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol 22:1736–1747. https://doi.org/10.1093/annonc/mdr304

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Dawood S, Hu R, Homes MD, Collins LC, Schnitt SJ, Connolly J, Colditz GA, Tamimi RM (2011) Defining breast cancer prognosis based on molecular phenotypes: results from a large cohort study. Breast Cancer Res Treat 126:185–192. https://doi.org/10.1007/s10549-010-1113-7

    Article  PubMed  Google Scholar 

  4. Hennigs A, Riedel F, Gondos A, Sinn P, Schirmacher P, Marme F, Jager D, Kauczor HU, Stieber A, Lindel K, Debus J, Golatta M, Schutz F, Sohn C, Heil J, Schneeweiss A (2016) Prognosis of breast cancer molecular subtypes in routine clinical care: a large prospective cohort study. BMC Cancer 16:734. https://doi.org/10.1186/s12885-016-2766-3

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Fizazi K, Tran N, Fein L, Matsubara N, Rodriguez-Antolin A, Alekseev BY, Ozguroglu M, Ye D, Feyerabend S, Protheroe A, Sulur G, Luna Y, Li S, Mundle S, Chi KN (2019) Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial. Lancet Oncol 20:686–700. https://doi.org/10.1016/S1470-2045(19)30082-8

    Article  CAS  PubMed  Google Scholar 

  6. Marciano A, Ingrasciotta Y, Isgro V, L’Abbate L, Foti SS, Picone A, Peditto M, Guzzo GM, Alibrandi A, Oteri G (2021) Cancer patients at risk for medication-related osteonecrosis of the jaw. A case and control study analyzing predictors of MRONJ onset. J Clin Med 10:4762. https://doi.org/10.3390/jcm10204762

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Zhou Y, Yu Y, Shi Y, Li M, Yang C, Wang S (2020) Combined administration of bisphosphonates, chemotherapeutic agents, and/or targeted drugs increases the risk for stage 3 medication-related osteonecrosis of the jaw: a 4-year retrospective study. Biomed Res Int 2020:5847429. https://doi.org/10.1155/2020/5847429

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Otto S, Aljohani S, Fliefel R, Ecke S, Ristow O, Burian E, Troeltzsch M, Pautke C, Ehrenfeld M (2021) Infection as an important factor in medication-related osteonecrosis of the jaw (MRONJ). Medicina (Kaunas) 57:463. https://doi.org/10.3390/medicina57050463

    Article  PubMed  Google Scholar 

  9. Kyrgidis A, Vahtsevanos K, Koloutsos G, Andreadis C, Boukovinas I, Teleioudis Z, Patrikidou A, Triaridis S (2008) Bisphosphonate-related osteonecrosis of the jaws: a case-control study of risk factors in breast cancer patients. J Clin Oncol 26:4634–4638. https://doi.org/10.1200/JCO.2008.16.2768

    Article  PubMed  Google Scholar 

  10. Vahtsevanos K, Kyrgidis A, Verrou E, Katodritou E, Triaridis S, Andreadis CG, Boukovinas I, Koloutsos GE, Teleioudis Z, Kitikidou K, Paraskevopoulos P, Zervas K, Antoniades K (2009) Longitudinal cohort study of risk factors in cancer patients of bisphosphonate-related osteonecrosis of the jaw. J Clin Oncol 27:5356–5362. https://doi.org/10.1200/JCO.2009.21.9584

    Article  CAS  PubMed  Google Scholar 

  11. Cabras M, Gambino A, Conrotto D, Garrone M, Fasciolo A, Basano L, Gilardetti M, Galassi C, Fusco V (2021) Survival of metastatic cancer and myeloma patients after diagnosis of osteonecrosis of jaws (ONJ). Potential impact on ONJ treatment strategies. Qeios. https://doi.org/10.32388/IKLIWH

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Dentistry and Oral Surgery, National Hospital Organization Hokkaido Cancer Center, 3-54 Kikusui 4-Jyo 2-Tyoume, Shiroishi-Ku, Sapporo, 003-0804, Japan

    Hironobu Hata, Kenji Imamachi & Kazuhito Yoshikawa

  2. Department of Oral Pathobiological Science, Faculty of Dental Medicine, Oral Diagnosis and Medicine, Hokkaido University, Nishi 7-Tyoume Kita 13-Jyo, Kita-Ku, Sapporo, 060-8586, Japan

    Kenji Imamachi, Kazuhito Yoshikawa, Jun Sato & Yoshimasa Kitagawa

  3. Department of Clinical Oral Oncology, National Hospital Organization Hokkaido Cancer Center, 3-54 Kikusui 4-Jyo 2-Tyoume, Shiroishi-Ku, Sapporo, 003-0804, Japan

    Michihiro Ueda

  4. Clinical Research Support Centre, Hirosaki University Hospital, 53 Honcho, Hirosaki, 036-8563, Japan

    Masashi Matsuzaka

  5. Department of Medical Informatics, Hirosaki University Hospital, 53 Honcho, Hirosaki, 036-8563, Japan

    Masashi Matsuzaka

  6. Department of Orthopaedic Surgery, National Hospital Organization Hokkaido Cancer Center, 3-54 Kikusui 4-Jyo 2-Tyoume, Shiroishi-Ku, Sapporo, 003-0804, Japan

    Hiroaki Hiraga

  7. Department of Rehabilitation, National Hospital Organization Hokkaido Cancer Center, 3-54 Kikusui 4-Jyo 2-Tyoume, Shiroishi-Ku, Sapporo, 003-0804, Japan

    Toshihisa Osanai

  8. Department of Urology, National Hospital Organization Hokkaido Cancer Center, 3-54 Kikusui 4-Jyo 2-Tyoume, Shiroishi-Ku, Sapporo, 003-0804, Japan

    Toru Harabayashi

  9. Department of Hematology, National Hospital Organization Hokkaido Cancer Center, 3-54 Kikusui 4-Jyo 2-Tyoume, Shiroishi-Ku, Sapporo, 003-0804, Japan

    Katsuya Fujimoto

  10. Department of Respiratory Medicine, National Hospital Organization Hokkaido Cancer Center, 3-54 Kikusui 4-Jyo 2-Tyoume, Shiroishi-Ku, Sapporo, 003-0804, Japan

    Satoshi Oizumi

  11. Department of Breast Surgery, Division of Surgery, Hokkaido University Graduate School of Medicine, Nishi 5-Tyoume Kita 14-Jyo, Kita-Ku, Sapporo, 060-8648, Japan

    Masato Takahashi

  12. Gerodontology, Department of Oral Health Science, Faculty of Dental Medicine, Hokkaido University, Nishi 7-Tyoume Kita 13-Jyo, Kita-Ku, Sapporo, 060-8586, Japan

    Yutaka Yamazaki

Authors
  1. Hironobu Hata
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kenji Imamachi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Michihiro Ueda
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Masashi Matsuzaka
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Hiroaki Hiraga
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Toshihisa Osanai
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Toru Harabayashi
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Katsuya Fujimoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Satoshi Oizumi
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Masato Takahashi
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Kazuhito Yoshikawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Jun Sato
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Yutaka Yamazaki
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Yoshimasa Kitagawa
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

All authors contributed to the article. The first draft of the manuscript was written by HH, and all authors commented on previous versions of the manuscript. The responses regarding the MRONJ study design for prognosis after bone metastasis of breast and prostate cancer were reviewed and edited by MT and TH. All authors read and approved the final manuscript.

Corresponding author

Correspondence to Hironobu Hata.

Ethics declarations

Ethics approval

All procedures performed on human participants were in accordance with the ethical standards of the institutional and national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. This single-center, retrospective, observational study protocol and patient information were approved by the Hokkaido Cancer Center Hospital Ethics Review Board (clinical study number 02–10), and informed consent was waived by this board because of the retrospective design of the study. Permission to access raw data from hospital cancer registries for life prognosis survey was also granted by the ethics review board.

Consent to participate

Informed consent was waived by the Hokkaido Cancer Center Hospital Ethics Review Board because of the retrospective design of the study.

Conflict of interest

The authors declare no competing interests.

Additional information

Publisher's note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Hata, H., Imamachi, K., Ueda, M. et al. Response to: Prognosis of metastatic bone cancer and myeloma patients and long‑term risk of medication‑related osteonecrosis of the jaw (MRONJ): some critical points. Support Care Cancer 30, 9693–9695 (2022). https://doi.org/10.1007/s00520-022-07434-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00520-022-07434-3

Search

Navigation